<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0020">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="ulist0010">
   <list-item id="u0010">
    <label>•</label>
    <p id="p0010">HDV infection is common among HBsAg-positive people worldwide.</p>
   </list-item>
   <list-item id="u0015">
    <label>•</label>
    <p id="p0015">Among HBsAg-positive people, estimated HDV prevalence is 4.5% (95% CI 3.6–5.7).</p>
   </list-item>
   <list-item id="u0020">
    <label>•</label>
    <p id="p0020">HDV prevalence in HBsAg-positive hepatology clinic attendees is 16.4% (14.6–18.6).</p>
   </list-item>
   <list-item id="u0025">
    <label>•</label>
    <p id="p0025">HDV prevalence is higher in people who inject drugs and who have HCV or HIV.</p>
   </list-item>
   <list-item id="u0030">
    <label>•</label>
    <p id="p0030">HDV causes an estimated 18% of cirrhosis and 20% of HCC associated with hepatitis B.</p>
   </list-item>
  </list>
 </p>
</abstract>
